Skip to NavigationSkip to content

Clive Dix appointed chairman of Crescendo Biologics

Published on: 21/01/10

Cambridge, UK-based Crescendo Biologics has appointed Clive Dix as chairman.

He will work closely with chief scientific officer Mike Romanos to drive the development of the company and its proprietary antibody fragment technologies following the recent £4.5 million seed round fundraising.

Dr Dix has a track record that spans more than 20 years in the pharmaceutical and biotech industries.

He is the chairman of the BioIndustry Association, the trade association for innovative enterprises in the UK's bioscience sector, and was previously co-founder and chief executive of PowderMed, the vaccines development company acquired by Pfizer in November 2006.

Prior to running PowderMed, Dr Dix was senior vice president, research and development and a board member of PowderJect Pharmaceuticals until its acquisition by Chiron Vaccines in 2003.

He began his career in industry at Ciba-Geigy before moving to GlaxoWellcome, which he left as UK research director in 2001.

Dr Dix is currently also non-executive chairman of Modern Biosciences and Auralis.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches